Zoetis (ZTS) Shares are Down -3.39%

Zoetis (ZTS) has risen sharply, recording gains of 0.57% in the past 4 weeks. However, the stock has corrected -3.39% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.79% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 1.16% and the fifty day Moving Average is 2.45%. Zoetis Inc. is up 7.81% in the last three month period. Year-to-Date the stock performance stands at 6.6%.

Zoetis (ZTS) : 7 Wall Street analysts covering Zoetis (ZTS) believe that the average level the stock could reach for the short term is $54.43. The maximum price target given is $62 and the minimum target for short term is around $49, hence the standard deviation is calculated at $5.5.


Zoetis (NYSE:ZTS): stock turned positive on Friday. Though the stock opened at $50.66, the bulls momentum made the stock top out at $51.16 level for the day. The stock recorded a low of $50.47 and closed the trading day at $50.76, in the green by 0.57%. The total traded volume for the day was 2,707,091. The stock had closed at $50.47 in the previous days trading.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.